H4 antagonist 48   Click here for help

GtoPdb Ligand ID: 9879

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 48 is an orally active, selective histamine H4 receptor antagonist that was developed as a potential therapy for the pruritis and inflammation associated with atopic dermatitis [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 84.13
Molecular weight 334.03
XLogP 2
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNC1CN(C1)c1nc2ncc(cc2n2c1nnn2)Br
Isomeric SMILES CNC1CN(C1)c1nc2ncc(cc2n2c1nnn2)Br
InChI InChI=1S/C11H11BrN8/c1-13-7-4-19(5-7)10-11-16-17-18-20(11)8-2-6(12)3-14-9(8)15-10/h2-3,7,13H,4-5H2,1H3
InChI Key ICGICUHMULRYIQ-UHFFFAOYSA-N
References
1. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. (2010)
The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation.
J Invest Dermatol, 130 (4): 1023-33. [PMID:19907432]
2. de Esch IJ, Thurmond RL, Jongejan A, Leurs R. (2005)
The histamine H4 receptor as a new therapeutic target for inflammation.
Trends Pharmacol Sci, 26 (9): 462-9. [PMID:16054239]
3. Fung-Leung WP, Thurmond RL, Ling P, Karlsson L. (2004)
Histamine H4 receptor antagonists: the new antihistamines?.
Curr Opin Investig Drugs, 5 (11): 1174-83. [PMID:15573868]
4. Ko K, Kim HJ, Ho PS, Lee SO, Lee JE, Min CR, Kim YC, Yoon JH, Park EJ, Kwon YJ et al.. (2018)
Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis.
J Med Chem, 61 (7): 2949-2961. [PMID:29579390]
5. Ohsawa Y, Hirasawa N. (2012)
The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice.
Allergy, 67 (8): 1014-22. [PMID:22686688]
6. Suwa E, Yamaura K, Oda M, Namiki T, Ueno K. (2011)
Histamine H(4) receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model.
Eur J Pharmacol, 667 (1-3): 383-8. [PMID:21664903]